EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories

Ioannis Psychogios, Yihan Hu, Christina Seitz, Emily E Joyce, Anikó Lovik, Caroline Ingre, Fang Fang

Journal of Neurology · 2025-01 · 272 (1)

DOI: 10.1007/s00415-024-12774-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurology, online erschienen am 12.12.2024. Verfasst von Ioannis Psychogios und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Biomarkers, Disease Progression. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, European Research Council Starting Grant, ATSDR CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Commonly measured clinical chemistry markers might be indicative of survival and disease progression in amyotrophic lateral sclerosis (ALS).

Methods

In a cohort study of 270 ALS patients diagnosed from April 2014 to May 2021 in Stockholm, Sweden, we examined the link between 29 clinical chemistry markers at diagnosis and mortality risk at 6 months, 1 year, and 3 years after diagnosis. Summary variables from exploratory factor analysis (EFA) assessed the markers’ collective impact on survival. We integrated ALS functional rating scale-revised (ALSFRS-R) scores with survival data using a joint latent class model to identify patterns of functional decline. Multinomial logistic regression determined how the EFA-derived factors predicted the decline trajectories post-diagnosis.

Results

Higher levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and albumin at diagnosis were linked to lower mortality in ALS patients, while increased neurofilament light chain (NfL), leukocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and carbon dioxide (CO 2 ) levels indicated higher mortality. The ‘Red blood cell profile’ factor, derived from EFA, emerged as a significant predictor of survival, independent of other prognostic indicators. The joint latent class model identified three distinct patient groups based on functional decline, with ‘Red blood cell profile’ suggesting a lower likelihood of being in the groups with slower progression.

Conclusion

Clinical chemistry markers, including NfL, lipids, albumin, leukocyte count, MCV, MCH, CO 2 , and the ‘Red blood cell profile,’ were associated with ALS survival. As these markers represent broader bodily functions, integrating them in ALS patient care could improve disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisBiomarkersDisease ProgressionHumansMaleFemaleMiddle AgedAgedCohort StudiesSwedenAdultPrognosis

Stichwörter der Autor:innen

ALSBlood markersClinical chemistryPrognosisSurvival

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Yihan.Hu@ki.se.
  • Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Yihan.Hu@ki.se.
  • Institute of Psychology, Leiden University, Leiden, The Netherlands.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Förderung

  • Swedish Research Council
  • European Research Council Starting Grant
  • ATSDR CDC HHS
  • CDC HHS
  • Centers for Disease Control and Prevention
  • Bjorklunds Fund
  • Ulla-Carin Lindquist Foundation
  • Neuro Sweden

Zitieren

APA

Psychogios, I., Hu, Y., Seitz, C., Joyce, E. E., Lovik, A., Ingre, C., & Fang, F. (2025). Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories. Journal of Neurology, 272(1). https://doi.org/10.1007/s00415-024-12774-7

Vancouver

Psychogios I, Hu Y, Seitz C, Joyce EE, Lovik A, Ingre C, et al. Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories. Journal of Neurology. 2025;272(1). doi:10.1007/s00415-024-12774-7

BibTeX
@article{Psychogios2025,
  author = {Psychogios, Ioannis and Hu, Yihan and Seitz, Christina and Joyce, Emily E and Lovik, Anikó and Ingre, Caroline and Fang, Fang},
  title = {Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories},
  journal = {Journal of Neurology},
  year = {2025},
  volume = {272},
  number = {1},
  doi = {10.1007/s00415-024-12774-7}
}
Kostenlos starten →